Cargando…

Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis

Multiple myeloma (MM) is the second most frequent hematologic cancer in the United States. Carfilzomib (CFZ), an irreversible proteasome inhibitor being used to treat relapsed and refractory MM, has been associated with cardiotoxicity, including heart failure. We hypothesized that a multi-omics appr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tantawy, Marwa, Chekka, Lakshmi Manasa, Huang, Yimei, Garrett, Timothy J., Singh, Sonal, Shah, Chintan P., Cornell, Robert F., Baz, Rachid C., Fradley, Michael G., Waheed, Nida, DeRemer, David L., Yuan, Lihui, Langaee, Taimour, March, Keith, Pepine, Carl J., Moreb, Jan S., Gong, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116486/ https://www.ncbi.nlm.nih.gov/pubmed/33996940 http://dx.doi.org/10.3389/fcvm.2021.645122

Ejemplares similares

Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center
por: Waheed, Nida, et al.
Publicado: (2021)

Comparison of Data Normalization Strategies for Array-Based MicroRNA Profiling Experiments and Identification and Validation of Circulating MicroRNAs as Endogenous Controls in Hypertension
por: Chekka, Lakshmi Manasa S., et al.
Publicado: (2022)

Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma
por: Tantawy, Marwa, et al.
Publicado: (2023)

Cardiotoxicity due to targeted anticancer agents: a growing challenge
por: Shah, Chintan P., et al.
Publicado: (2019)

Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials
por: Shah, Chintan, et al.
Publicado: (2018)

Carfilzomib induced cardiotoxicity in a multiple myeloma patient
por: Méndez-Toro, Arnold, et al.
Publicado: (2020)

Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma
por: Ikoma, Takenori, et al.
Publicado: (2019)

Racial and Ethnic Differences in Cardiac Surveillance Evaluation of Patients Treated With Anthracycline‐Based Chemotherapy
por: DeRemer, David L., et al.
Publicado: (2023)

Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
por: Astarita, Anna, et al.
Publicado: (2023)

Epigenetic Changes Associated With Anthracycline‐Induced Cardiotoxicity
por: Tantawy, Marwa, et al.
Publicado: (2020)

Elucidating Carfilzomib’s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin
por: Efentakis, Panagiotis, et al.
Publicado: (2021)

Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Buck, Benjamin, et al.
Publicado: (2022)

Clinically Relevant Drug Interactions in the Cancer Setting
por: DeRemer, David
Publicado: (2022)

Zingerone Attenuates Carfilzomib-Induced Cardiotoxicity in Rats through Oxidative Stress and Inflammatory Cytokine Network
por: Alam, Mohammad Firoz, et al.
Publicado: (2022)

Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma
por: Yang, Eric H., et al.
Publicado: (2018)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
por: DeRemer, David L, et al.
Publicado: (2011)

Management of Warfarin Anticoagulated Patients Choosing Hyperbaric Oxygen Treatments
por: DeRemer, Christina E., et al.
Publicado: (2019)

Exploring VEGF-Linked Pathways: Investigating Multiple miRNAs for Their Therapeutic Potential in Angiogenesis Targets and as Biomarkers in Recurrent Glioblastoma Multiforme
por: Hadizadeh, Morteza, et al.
Publicado: (2022)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib
por: Shen, Xuxing, et al.
Publicado: (2021)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis
por: Bishnoi, Rohit, et al.
Publicado: (2020)

Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity
por: Diwadkar, Sachin, et al.
Publicado: (2016)

Molecular docking and mouse modeling suggest CMKLR1 and INSR as targets for improving PCOS phenotypes by minocycline
por: Kian, Mahdie, et al.
Publicado: (2022)

Variability in the Calculation of Time in Therapeutic Range for the Quality Control Measurement of Warfarin
por: Siddiqui, Safia, et al.
Publicado: (2018)

A Novel Simple Method for Determining CYP2D6 Gene Copy Number and Identifying Allele(s) with Duplication/Multiplication
por: Langaee, Taimour, et al.
Publicado: (2015)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis
por: Kawaguchi-Suzuki, Marina, et al.
Publicado: (2018)

Genome‐wide Association Study Identified Chromosome 8 Locus Associated with Medication‐Related Osteonecrosis of the Jaw
por: Yang, Guang, et al.
Publicado: (2021)

Impact of an ambulatory care pharmacist on provider relative value units in a rural clinic
por: DeRemer, Christina E., et al.
Publicado: (2021)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
por: Facon, Thierry, et al.
Publicado: (2022)

Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing Escherichia coli among Uropathogens of Pediatrics in North of Iran
por: Rezai, Mohammad Sadegh, et al.
Publicado: (2015)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
por: Rosenthal, A, et al.
Publicado: (2016)

Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
por: Español, Ignacio, et al.
Publicado: (2017)

Optimizing carfilzomib use in multiple myeloma treatment
por: Yoon, Sung-Soo
Publicado: (2019)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
por: Claudiani, Simone, et al.
Publicado: (2021)

Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis
por: Eigbire-Molen, Odianosen, et al.
Publicado: (2022)

Carfilzomib Induced Microangiopathy due to Accumulation With Paxlovid
por: Philipponnet, Carole, et al.
Publicado: (2022)

An Untargeted Metabolomics Approach on Carfilzomib-Induced Nephrotoxicity
por: Barla, Ioanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9o7gns0v9cspdi5b9chr71672m